StreetAlpha.app
Home › Stocks › UTHR

UNITED THERAPEUTICS Corp (UTHR)

Healthcare
$584.10
▼ −0.64%
LAST CLOSE · NOV 17

United Therapeutics develops and sells drugs for pulmonary arterial hypertension and other rare diseases from its base in Silver Spring, Maryland. It last closed at $584.10 on Nov 17, down 0.64% on the day. The average 12-month price target from 9 analysts is $651.44 (+11.5% from the last close), with a high of $768.00 and a low of $321.00. Analyst consensus is Buy, based on the latest ratings from 9 firms (7 buy, 1 hold, 1 sell). Over the past 90 days StreetAlpha recorded 7 whale options trades in UTHR, 57% of them bullish and 43% bearish. In the past 30 days there were 9 dark pool prints totaling $23.8M, the largest $14.5M.

AI Auto Pilots
Is UTHR in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$3.2B
+1.9% vs a year ago
Net income
$1.2B
−3.2% vs a year ago
EPS (diluted)
$26.49
+0.4% vs a year ago
Free cash flow
$867.2M
27.2% margin
Valuation
Market cap
$24.9B
42.6M shares
P/E
22.0
Price over 12 month EPS
Price to sales
7.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$1.2B
At Sep 30
Shareholder equity
$6.3B
Buybacks
$2.0B
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $1.7B$1.7BFY2021FY2022: $1.9B$1.9BFY2022FY2023: $2.3B$2.3BFY2023FY2024: $2.9B$2.9BFY2024FY2025: $3.2B$3.2BFY2025

From UTHR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Buy
Based on 9 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
9firms
7 Buy1 Hold1 Sell
Each firm's latest rating on UTHR in the past 90 days
Average 12-month target
$651.44
▲ 11.5% upside

Based on 9 analysts who set a price target on UTHR in the past 90 days. The average target is $651.44, with a high of $768.00 and a low of $321.00, compared with the last close of $584.10.

$285$458$631$804PAST 11 TRADING DAYS12-MONTH TARGETSHIGH $768AVG $651.44LOW $321Jun 5LAST CLOSE+12 MO$285$458$631$804PAST 11 DAYSTARGETSHIGH $768AVG $651.44LOW $321Jun 5LAST CLOSE+12 MO
Highest target$768.00
Average target$651.44
Lowest target$321.00
Latest rating changes
HC Wainwright & Co.Assumed coverage
Nov 9Buy$660
TD CowenMaintained
Nov 5Buy$700
RBC CapitalTarget raised
Nov 5Buy$697 → $725
Wells FargoTarget lowered
Nov 5Buy$738 → $703
BTIGTarget raised
Nov 4Buy$728 → $768
DateFirmActionRatingPrice target
Nov 9HC Wainwright & Co.Assumed coverageBuy$660
Nov 5TD CowenMaintainedBuy$700
Nov 5RBC CapitalTarget raisedBuy$697 → $725
Nov 5Wells FargoTarget loweredBuy$738 → $703
Nov 4BTIGTarget raisedBuy$728 → $768
Loading…

Technical Analysis

UTHR · as of the Nov 17 close · updated after every close
Uptrend

The stock sits between its 20 and 50 day averages. It is 8% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 55). The nearest support is the Pivot at $583.66, and the nearest resistance the swing high (Oct 1) at $585.79.

Short trendBullish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityHigh, 3.1%/day
Key levels
$614.2352 week high+5.2%
$591.42Pivot R1+1.3%
$587.7920 day average+0.6%
$585.79Swing high (Oct 1)+0.3%
$584.10Last close
$583.66Pivot−0.1%
$576.33Pivot S1−1.3%
$556.63Swing low (Nov 9)−4.7%
$546.3450 day average−6.5%
$538.60200 day average−7.8%
$535.56100 day average−8.3%
$455.6352 week low−22.0%
Indicators
RSI (14)54.54Middle of its rangeNeutral
MACD10.81Below its signal lineBearish
Stochastic54.0Middle of its rangeNeutral
ADX (14)19.5No clear trend
Williams %R-52.3Oversold below −80, overbought above −20Neutral
CCI (20)-24.8Oversold below −100, overbought above 100Neutral
Rate of change−2.9%Change over 10 sessionsBearish
ATR (14)$17.88Typical daily range, 3.1% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for UTHR

What happened before

See how UTHR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow is mixed4 bullish and 3 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow UTHR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How UTHR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
7
Bullish
4
57%
Bearish
3
43%
Date span
Sep 11 – Nov 16
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
9
Notional
$23.8M
Largest print
$14.5M
Loading…

UTHR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▼367 buying vs 450 selling
  • ▲Held by funds +2.0 pts
  • ▼Funds holding -39
  • ▼Superinvestors: 2 added, 3 cut
  • ▲Put/call 0.86 to 0.73
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding846885−4.4%
In funds' top 102318+27.8%
Held by funds100.6%98.6%+2.0 pts
New / increased80 / 287100 / 318−12.2%
Reduced / sold out333 / 117331 / 72+11.7%
Put/call ratio0.730.86−15.2%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See UTHR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether UTHR is in one of them and how their past UTHR trades turned out.

UTHR in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered UTHR in an article yet. Here's the latest on the wider market.

UTHR Congress Trades

All congress trades →
Trades, 12 months
3
Buys
1
33%
Sells
2
67%
People
1
Last filed Nov 21
Who traded UTHR · since 2019
Latest 5 filings of 19
$1K – $15KTraded Oct 31, 2025Filed Nov 21, 2025
$1K – $15KTraded Oct 30, 2025Filed Nov 21, 2025
$1K – $15KTraded Oct 30, 2025Filed Nov 21, 2025
$15K – $50KTraded Oct 27, 2025Filed Nov 10, 2025
$1K – $15KTraded Jun 11, 2025Filed Aug 13, 2025
PersonTypeAmountTradedFiledDelay
Lisa McClainR · MISell$1K – $15KOct 31, 2025Nov 21, 202521 d
Lisa McClainR · MISell$1K – $15KOct 30, 2025Nov 21, 202522 d
Lisa McClainR · MIBuy$1K – $15KOct 30, 2025Nov 21, 202522 d
Michael McCaulR · TXSell$15K – $50KOct 27, 2025Nov 10, 202514 d
Lisa McClainR · MIBuy$1K – $15KJun 11, 2025Aug 13, 202563 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About UNITED THERAPEUTICS

United Therapeutics is a pharmaceutical company based in Silver Spring, Maryland. It develops and sells treatments for rare diseases, mainly pulmonary arterial hypertension, a serious condition that affects the blood vessels in the lungs. Its main products include the Tyvaso DPI and Nebulized Tyvaso inhaled treatments, Remodulin, Orenitram, and Adcirca, which it sells in the United States to specialty pharmaceutical distributors. The company also sells Unituxin for high risk neuroblastoma, a cancer, and is developing treatments for other lung diseases.

Headquarters
Silver Spring, MD